Author(s):
Suman Kumar Rathore, Mohammad Akhtar Rasool, Aman Tiwari, Pratyush Kumar Brahma, Vijaya Kumar Meher
Email(s):
mohammadakhtarrasool@gmail.com
DOI:
10.52711/0974-360X.2025.00333 
Address:
Suman Kumar Rathore1, Mohammad Akhtar Rasool2*, Aman Tiwari3, Pratyush Kumar Brahma4, Vijaya Kumar Meher5
1,2Tagore Institute of Pharmacy and Research, Bilaspur, Chhattisgarh, India.
3,4School of Pharmacy, Rai University, India.
5School of Pharmacy, Centurion University of Technology and Management, India.
*Corresponding Author
Published In:
Volume - 18,
Issue - 5,
Year - 2025
ABSTRACT:
Drugs that have limited absorption window in the gastrointestinal tract will have poor absorption. For these drugs, gastro-retentive drug delivery systems offer the advantage in prolonging the gastric emptying time. The aim of formulating floating tablets of ciprofloxacin was to prolong the gastric residence time after oral administration to accomplish the controlled release of drug. Ciprofloxacin, a broad-spectrum fluoroquinolone antibacterial agent and it is use in the treatment of bone and joint infections, diarrhoeal infection, lower respiratory tract infections, urinary tract infections and meningococcal prophylaxis. Floating tablets of ciprofloxacin were prepared by direct compression method using different grades (K-15 and K-4) of Hydroxyl Propyl Methyl Cellulose (HPMC) and PVP K30 using effervescent technique. Sodium bicarbonate was incorporated as a gas-generating agent. The effect of citric acid on drug release profile and floating assets was also examined. FTIR studies adapted that there was no incompatibility between the polymers and the drug. Tablet pre-formulation parameters were within the pharmacopoeias limit. Tablets were estimated by different parameters such as weight uniformity, content uniformity, thickness, hardness, in vitro release studies, resistance determination and kinetic analysis of dissolution data. Tablet showed = 1min lag time, continuation of resistance for >12 h. The in-vitro drug release pattern of optimized ciprofloxacin floating tablets (F7) was fitted to different kinetic models which showed highest regression (r2 =0.983) for first order kinetics. Ciprofloxacin floating tablets exhibited increased gastric residence time, there by improved bioavailability and therapeutic effect of the drug.
Cite this article:
Suman Kumar Rathore, Mohammad Akhtar Rasool, Aman Tiwari, Pratyush Kumar Brahma, Vijaya Kumar Meher. Formulation, Development and Evaluation of Novel Gastroretentive Sustaine Release of Ciprofloxacin HCl Floating Matrix Tablet. Research Journal of Pharmacy and Technology. 2025;18(5):2329-4. doi: 10.52711/0974-360X.2025.00333
Cite(Electronic):
Suman Kumar Rathore, Mohammad Akhtar Rasool, Aman Tiwari, Pratyush Kumar Brahma, Vijaya Kumar Meher. Formulation, Development and Evaluation of Novel Gastroretentive Sustaine Release of Ciprofloxacin HCl Floating Matrix Tablet. Research Journal of Pharmacy and Technology. 2025;18(5):2329-4. doi: 10.52711/0974-360X.2025.00333 Available on: https://rjptonline.org/AbstractView.aspx?PID=2025-18-5-56
REFERENCES:
1. Venkateswarlu K, Shanthi A. Formulation and evaluation of sustained release glipizide matrix. IOSR J Pharm Biol Sci. 2012; 2: 17-23.
2. Naik SB, Venkateswarlu K, Chandrasekhar KB. Formulation and in-vitro evaluation of orodispersible tablets of olanzapine for the improvement of dissolution rate. J Chem Pharm Res.2016; 8: 177-81.
3. Naik SB, Venkateswarlu K, Chandrasekhar KB. Formulation and evaluation of oxybutynin chloride extended release matrix tablets. Indo Am J Pharm Res 2016; 6: 4179-84.
4. Shivakumar HG, Gowda DV, Pramodkumar TM. Floating controlled drug delivery systems for prolonged gastric residence. Indian J Pharm Educ Res. 2004; 38: 172-80.
5. Varshosaz J, Tavakoli N, Roozbahani F. Formulation and in vitro characterization of ciprofloxacin floating and bioadhesive extended-release tablets. Drug Deliv. 2006; 13: 277-85.
6. Mathur P, Saroha K, Syan N, Verma S, Kumar V. Floating drug delivery systems: An innovative acceptable approach in gastroretentive drug delivery. Arch Appl Sci Res. 2010; 2: 257-70.
7. Iannuccelli V, Coppi G, Bernabei MT, Cameroni R. Air compartment multiple-unit system for prolonged gastric residence. Int J Pharm. 1998; 174: 47-54.
8. Ichikawa M, Watanabe S, Miyake Y. A new multiple-unit oral floating dosage system. I: Preparation and in vitro evaluation of floating and sustained-release characteristics. J Pharm Sci. 1991; 80: 1062-6.
9. Klausner EA, Lavy E, Friedman M, Hoffman A. Expandable gastroretentive dosage forms. J Control Release. 2003; 90: 143-62.
10. Atyabi F, Sharma HL, Mohammad HA, Fell JT. Controlled drug release from coated floating ion exchange resin beads. J Control Release. 1996; 42: 25-8.
11. Atyabi F, Sharma HL, Mohammad HA, Fell JT. A novel floating system using ion exchange resins. Proceedings of the 21st International Symposium on Controlled Release of Bioactive Materials, 1994 June 27-30, Nice, France.
12. Gronia R, Heun G. Oral dosage forms with controlled gastrointestinal transit. Drug Dev Ind Pharm. 1984; 10: 527-39.
13. Atyabi F, Sharma HL, Mohammad HA, Fell JT. In-vivo evaluation of a novel gastroretentive formulation based on ion exchange resins. J Control Release. 1996; 42: 105-13.
14. Rocca JG, Omidian H, Shah K. Progress in gastroretentive drug delivery systems. Business Briefing PharmaTech. 2003; 5: 152-6.
15. Streubel A, Siepmann J, Bodmeier R. Drug delivery to the upper small intestine window using gastroretentive technologies. Curr Opin Pharmacol. 2006; 6: 501-8.
16. Preda M, Leucuta SE. Oxprenolol-loaded bioadhesive microspheres: Preparation and in vitro/in vivo characterization. J Microencapsul 2003; 20: 777-89.
17. Singh BM, Kim KH. Floating drug delivery systems: An approach to oral controlled drug delivery via gastric retention. J Control Release. 2000; 63: 235-59.
18. Nelson JM, Chiller TM, Powers JH, Angulo FJ. Fluoroquinolone-resistant campylobacter species and the withdrawal of fluoroquinolones from use in poultry. Clin Infect Dis. 2007; 44: 977-80.
19. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997; 61: 377-92.
20. Tadros MI. Controlled-release effervescent floating matrix tablets of ciprofloxacin hydrochloride: Development, optimization and in vitro–in vivo evaluation in healthy human volunteers. Eur J Pharm Biopharm. 2009; 74: 332-7.
21. Desai S, Bolton S. A floating controlled release system: in-vitro and in-vivo evaluation. J Pharm Res 1993: 10; 1321-5.
22. Sakore S, Chakraborty B. Formulation and evaluation of enalapril maleate sustained release matrix tablets. Int J Pharm Biomed Res. 2013; 4: 21-6.
23. Udayakumar T, Suresh AG, Ubaidulla U. Formulation and evaluation of immediate and sustained release bilayered tablet with glibenclamide and metformin Hcl. Int J Res Dev Pharm Sci. 2013; 2: 337-43.
24. Shashidhar P, Vidya Sagar G, Srikanth G. Design and in-vitro evaluation of metformin hydrochloride (SR) and glimepiride (IR) as bilayered tablets. Int J Pharm Chem Sci. 2013; 2: 780-92.
25. Sridhar Babu G, Vijay Kumar D, Aishwarya M, Malathy PS, Redya Naik R. Formulation and in vitro characterization of sustained release matrix tablets of metformin HCl. J Glob Trends Pharm Sci. 2014; 5: 2085-92.
26. Saluja V, Garg C. Once-daily sustained-release matrix tablets of metformin hydrochloride based on an enteric polymer and chitosan. J Pharm Educ Res. 2013; 4: 92-7.
27. T. Salsa, F. Veiga, M.E. Pina. Drug Dev Ind Pharm. 1997; 23: 929-938.
28. Varshosaz, J.; Tavakoli, N.; Eram, S.A. Use of natural gums and cellulose derivatives in production of sustained release metoprolol tablets. Drug Del. 2006; 13(2): 113-119.
29. Potu Apparao, Jyothi, Veerareddy Prabhakarreddy, Jukanti Raju and Burra ShashidherFormulation and evaluation of gum based matrix tablets of Lamivudine. Der Pharmacia Sinica. 2011; 2(3): 176-192.